Reply:
W. Ray Kim, Terry M. Therneau – 29 July 2008
Reply:
Joanne B. Krasnoff, Nathan M. Bass, Patricia L. Painter, Raphael B. Merriman – 29 July 2008
Weight‐adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short‐term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection
Martin Lagging, Nina Langeland, Court Pedersen, Martti Färkkilä, Mads Rauning Buhl, Kristine Mørch, Amar P. Dhillon, Åsa Alsiö, Kristoffer Hellstrand, Johan Westin, Peer Christensen, Peter Leutscher, Gunnar Norkrans – 29 July 2008
Reply:
Chia‐Ming Chu – 16 July 2008
Hereditary hemochromatosis in the post‐HFE era
John K. Olynyk, Debbie Trinder, Grant A. Ramm, Robert S. Britton, Bruce R. Bacon – 16 July 2008 – Following the discovery of the HFE gene in 1996 and its linkage to the iron overload disorder hereditary hemochromatosis (HH) there have been profound developments in our understanding of the pathogenesis of the biochemical and clinical manifestations of a number of iron overload disorders.
Benefits of “the benefit model” in liver transplantation
W. Ray Kim, Walter K. Kremers – 9 July 2008
Fast break on the fat brake: Mechanism of peroxisome proliferator‐activated receptor‐δ regulation of lipid accumulation in hepatocytes
Danielle B. Andrews, Jeffrey B. Schwimmer, Joel E. Lavine – 9 July 2008
Reply:
Winston Dunn, Jeffrey B. Schwimmer – 9 July 2008
Reply:
Nathan A. Johnson, Toos Sachinwalla, Jacob George – 8 July 2008